Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1α activity and vascular endothelial growth factor expression in small cell lung cancer cells

Molecular Cancer Therapeutics

Volumn 5, Issue 6, 2006, Pages 1415-1422

  Litz, Julie ^a   Krystal, Geoffrey W ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; STEM CELL FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ACTIVATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENE MUTATION; GENETIC TRANSFECTION; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; REPORTER GENE; RNA STABILITY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MUTATION; PIPERAZINES; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RNA, MESSENGER; SIGNAL TRANSDUCTION; STEM CELL FACTOR; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33746072622     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0503     Document Type: Article

References (33)

1. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
2. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
3. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
5. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
6. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.
7. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996;271: 2746-53.
8. Liu LX, Lu H, Luo Y, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1 . Biochem Biophys Res Commun 2002;291:908-14.
9. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993;268: 21513-8.
10. Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 2000;275:21048-54.
11. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002;277:38205-11.
12. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004.
13. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999;274:32631-7.
14. Zhang W, Stoica G, Tasca SI, Kelly KA, Meininger CJ. Modulation of tumor angiogenesis by stem cell factor. Cancer Res 2000;60:6757-62.
15. Heissig B, Werb Z, Rafii S, Hattori K. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb Haemost 2003;90:570-6.
16. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004;96:46-55.
17. Litz J, Warshamana-Greene GS, Sulanke G, Lipson KE, Krystal GW. The multi-targeted kinase inhibitor SU5416 inhibits SCLC growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 2004;46:283-91.
18. Lloyd KP, Krystal GW. Role of small-molecule Kit receptor tyrosine kinase inhibitors in the treatment of SCLC. Clin Lung Cancer 2002;3: 213-8.
19. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002;86:558-63.
20. Mall JW, Schwenk W, Philipp AW, et al. Serum vascular endothelial growth factor levels correlate better with tumour stage in SCLC than albumin, neuron-specific enolase or lactate dehydrogenase. Respirology 2002;7:99-102.
21. Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor ST1571 inhibits SCLC growth. Clin Cancer Res 2000;6:3319-26.
22. Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of SCLC cell lines having classic and variant features. Cancer Res 1985;45:2913-23.
23. Krystal G, Birrer M, Way J, et al. Multiple mechanisms for transcriptional regulation of the myc gene family in SCLC. Mol Cell Biol 1988;8:3373-81.
24. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
25. Park GH, Plummer HK III, Krystal GW. Selective Spl binding is critical for maximal activity of the human c-kit promoter. Blood 1998;92: 4138-49.
26. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular enclothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998;273:6417-23.
27. Arsham AM, Plas DR, Thompson CB, Simon MC. Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res 2004;64:3500-7.
28. Pore N, Liu S, Shu HK, et al. Spl is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell 2004;15:4841-53.
29. Brahimi-Horn C, Mazure N, Pouysségur J. Signalling via the hypoxia-inducible factor-1α requires multiple posttranslational modifications. Cell Signal 2005;17:1-9.
30. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-65.
31. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/ phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60:1541-5.
32. Takahashi R, Tanaka S, Kitadai Y, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 2003;64:266-74.
33. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-703.